Mandatory Hubs and Limited Distribution: Hidden Friction Points Impacting Prescription Conversion

 By Brian Bamberger, General Manager, Life Sciences 

Pharmaceutical manufacturers have long relied on mandatory hub models and limited specialty pharmacy networks to control patient access, support services, and data visibility. This is particularly true for complex or newly launched therapies.

Healthcare delivery has been consolidating around the electronic health record (EHR), and workflows that require care providers to go outside of the EHR create unintended friction that can directly impact prescription fulfillment and patient access.

This tension is becoming more costly.

The Growing Disconnect Between Manufacturer Strategy and Provider Workflow

Health systems are undergoing a fundamental shift. There is a growing expectation that operational workflows that require clinical and/or administrative data occur entirely within the EHR. Processes are being automated to remove the need for faxes, portals, and duplicate entry. This includes prior authorization (PA).

These changes are driven by both technological advancements and policy pressure, resulting in a more streamlined but also more rigid provider experience. A notable accelerant of this shift is the Centers for Medicare and Medicaid Services’ Electronic Prior Authorization Initiative, which mandates a transition to standardized, native EHR workflows by 2027 so as to eliminate the administrative burden that currently costs providers billions annually.

Prescribers’ expectations are simple:

If it’s not in the EHR, it’s not part of the workflow.

Where Mandatory Hubs and Limited Distribution Break Down

Mandatory hubs and limited distribution networks are often designed to improve coordination, oversight, and patient access for complex therapies. In practice, however, they can introduce significant operational friction into prescribing workflows as EHR-based prescribing, electronic prior authorization, and integrated clinical workflows continue to mature.

Several recurring breakdown points continue to surface across the industry:

1. “Lost Prescriptions” Are a Real—and Growing—Problem
2. EHRs Lack Visibility into Specialty Pharmacy Restrictions
3. Payer Networks Add Another Layer of Complexity
4. EHR-Based Prior Authorization Is Increasing Workflow Stickiness

One of the most critical friction points is described as “lost prescriptions.”

These occur when:

• A prescription is sent to a pharmacy that is not authorized to dispense the product.
• The receiving pharmacy does not reroute, act, or adequately notify the provider or patient.
• The prescription stalls, delays, or never gets filled.

In many cases:

• The provider is unaware of the issue.
• The patient is left without therapy.
• The prescription effectively “disappears” in the system.

This workflow disruption carries a heavy clinical toll; peer-reviewed data published in the Journal of Managed Care & Specialty Pharmacy demonstrates that administrative hurdles and fragmented routing can drive prescription abandonment rates as high as 78% for complex therapies, directly impacting primary medication adherence. This is not a rare exception—it is a predictable outcome of misaligned distribution and workflow design.

Core structural issues include:

• EHRs do not contain a standardized, comprehensive list of eligible specialty pharmacies for each drug.
• Each product has its own unique network, often changing over time.
• There is no single source of truth integrated into prescribing workflows.

As a result:

• Providers cannot easily determine where a prescription should be sent.
• Prescriptions are frequently routed incorrectly on the first attempt.

This lack of embedded intelligence creates systemic inefficiency exactly at the point of prescribing. Real-world operational impacts of this data gap are stark. Research featured in the Journal of Oncology Pharmacy Practice highlights that navigating limited-distribution drug (LDD) networks, even after insurance approval is secured, can add an average 5.2 days to a patient's overall time to therapy due to logistical handoffs outside the main clinical flow.

Even when manufacturers define a limited distribution network, that is only part of the equation.

Payers often impose their own specialty pharmacy requirements and contractual routing rules that may conflict with the manufacturer’s intent.

This creates a multi-layered routing problem:

• Manufacturer network.
• Payer network.
• Provider workflow.

Without alignment across all three, friction is inevitable.

The shift to EHR-integrated PA further amplifies the issue:

• Prior authorization is being completed directly within the EHR.
• Patient data is increasingly autopopulated from the medical record.
• The process is becoming more efficient, but also more embedded.

This reduces the likelihood that providers will leave the EHR to complete external hub forms or manually intervene when routing issues occur.

In effect, the more efficient the EHR becomes, the less tolerant users are of external, manual steps, and mandatory hub models often sit outside that optimized flow.

The Strategic Tradeoff: Data Control vs. Access Friction

To be clear, limited distribution and mandatory hubs are not without value.

Manufacturers benefit from:

• High-quality, centralized patient data.
• Better visibility into initiation, adherence, and outcomes.
• More control during early launch phases.

There is legitimate strategic value in maintaining a smaller, controlled pharmacy network

However, the tradeoff is now more pronounced:

The commercial risk of prioritizing data control over workflow alignment is further illuminated by industry tracking on strategies to increase speed to therapy, which shows that when administrative delays push turnaround times into weeks, prescription abandonment skyrockets. This is particularly true if out-of-pocket costs aren't clearly surfaced within that initial prescribing window.

A New Imperative: Designing for the EHR-First Reality

Success increasingly depends on how well a therapy fits into provider workflows, not just its clinical profile or distribution design.

For brand teams, that means the distribution strategy must be operationalized inside the EHR, not adjacent to it.

Key considerations include:

• Ensuring prescribing workflows route accurately on the first attempt.
• Minimizing the need for providers to exit the EHR.
• Reducing reliance on manual hub-driven processes.
• Aligning distribution strategy with payer realities and EHR capabilities.

What This Means for Pharmaceutical Brand Teams

For commercial, access, and patient services leaders, this shift demands a reevaluation of long-standing assumptions:

• Limited distribution may introduce material access barriers.
• Hub dependency may create workflow discontinuity.
• Data strategy must be balanced against conversion and fulfillment risk.

The key question is no longer:

“How do we maintain control?”

But rather:

“How do we enable access within the realities of modern clinical workflows?”

Reducing Friction Without Losing Insight

As workflows evolve, mandatory hubs and limited distribution models will become less aligned with how care is delivered today.

The opportunity is not to abandon these models but to adapt them in ways that preserve selective data capture while eliminating the friction that leads to lost prescriptions and delayed care.

The brands that succeed will be those that:

• Treat EHR workflow as a core commercialization channel.
• Design access models that work with—not against—provider behavior.

What Can Your Organization Do to Better Leverage in-EHR Functions?

Navigating today’s EHR-driven care environment requires more than traditional market access strategies. It requires an understanding of how provider workflows, health information technology (health IT) systems, and operational realities intersect in practice with new technologies and automation.

Ensuring that prescribing workflows are configured to route accurately to the appropriate specialty pharmacies within the EHR is a critical success factor. Organizations aligning distribution strategy with real-world clinical workflows will be better positioned to reduce friction, improve access, and maximize therapy adoption. With decades of experience in healthcare interoperability and health IT, Point-of-Care Partners (POCP) helps life sciences manufacturers address these challenges.

Our Life Sciences team brings deep familiarity with the functionality and workflow considerations of widely used EHR platforms, helping clients better understand how patient support, access, and distribution strategies may be experienced in real-world clinical settings.

POCP supports clients through practical services, including development of accurate EHR field guides, educational resources, workflow-focused training, and ongoing support to help teams navigate questions and challenges as they arise.

Contact me to discuss your organization’s specific challenges and explore how POCP can support your access and engagement goals in an increasingly “EHR first” healthcare environment.